AIxCrypto Holdings (AIXC) Registration filing summary

Company overview and business model

• Focuses on early-clinical-stage therapeutics for adult and pediatric cancer, with lead program QN-302 in Phase 1a trials and a preclinical Pan-RAS program targeting oncogene protein interactions.

• Holds a minority stake in NanoSynex, an Israeli diagnostics company, and has a royalty-based co-development agreement with Marizyme for DuraGraft, a vascular conduit solution.

• Recently divested its diagnostics business and is no longer pursuing gastrointestinal disease treatments.

Financial performance and metrics

• As of June 30, 2024, reported a working capital deficiency and recurring operating losses, raising substantial doubt about ability to continue as a going concern.

• Net tangible book value after the offering is projected at $0.01 per share, with immediate dilution of $0.12 per share to new investors.

• Recent public offering in September 2024 raised $3.47 million in gross proceeds.

Use of proceeds and capital allocation

• Net proceeds of up to $1.8 million will be used for operations, general corporate purposes, $800,000 for marketing, working capital, clinical and preclinical advancement, and possible acquisitions.

• If less than $1.8 million is raised, the marketing payment will not be made and all proceeds will go to working capital and other stated purposes.